X
Logo IZB Innovations- und Gründerzentrum Biotechnologie
IZB Signet

Networking meeting with the partners of the Life Sciences Platform at the IZB

Interesting presentations on innovations and industry dynamics. 30 multipliers of the biotech industry accepted the invitation of the “Platform Life Sciences” on November 16, 2022 to the Faculty Club G2B (Gateway to Biotech) at the Innovation and Start-up Center Biotechnology (IZB). Six exciting presentations later led to lively discussions among the participants.
November 2022
Netzwerktreffen Mit Den Partnern Der Plattform Life Sciences Im IZB
© IZB
Dr. Markus Rieger, Executive Board GoingPublic Media; Dr. Viola Bronsema, Managing Director BIO Germany; Dr. Kerstin Bode, MD, PhD, Managing Director of Bioscience Valuation BSV; Karin Hofelich, Publishing Director Plattform Life Sciences; Dr. Frauke Hangen, Managing Director BioRiver; Dr. Peter Hanns Zobel, Managing Director IZB; Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM Isotope Technologies Munich (f.r.t.l.)
“The start-ups already based at the IZB have raised a total of EUR four billion in capital through deals or financing since 2015 alone. And with companies such as Atriva Therapeutics, Tubulis, Insempra and Invitris recently added to the site in 2022, this trend continues unabated.”
Dr. Peter Hanns Zobel Managing Director IZB
Programm

  • “Growth Dynamics at the IZB”, Dr. Peter Hanns Zobel, Managing Director of the Biotechnology Innovation and Start-up Center (IZB)
  • “There’s something going on – scalding reports from interactions with government on technological sovereignty, bioeconomy and industrial health economy”, Dr. Viola Bronsema, Managing Director BIO Germany.
  • “How R&D strategy impacts value”, Kerstin M. Bode-Greuel, MD, PhD, Managing Director Bioscience Valuation BSV.
  • ‘”Theranostics – The modern targeted way of cancer treatment”‘, Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations ITM Isotope Technologies Munich
  • ‘”German Health Data: How much longer lean food for our healthcare industry?”,  Dr. Jens Wiehler, Managing Director DigiMed Bavaria, BioM Biotech Cluster Development.
  • “30 stocks, 5 exchanges – the Biotech & Co. Basket”, Markus Rieger, Board of Directors GoingPublic Media

Fördergesellschaft IZB mbH
Fördergesellschaft IZB mbH

Am Klopferspitz 19

82152 Planegg / Martinsried

Germany

Tel.: +49 (0)89/552 7948-17

Marketing@izb-online.dewww.izb-online.de
menuchevron-down
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.